Cargando…
Editorial: Inhibitors of CDK family: New perspective and rationale for drug combination in preclinical models of solid tumors
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086415/ https://www.ncbi.nlm.nih.gov/pubmed/37056348 http://dx.doi.org/10.3389/fonc.2023.1180650 |
| _version_ | 1785022147972825088 |
|---|---|
| author | Cavazzoni, Andrea Palladini, Arianna |
| author_facet | Cavazzoni, Andrea Palladini, Arianna |
| author_sort | Cavazzoni, Andrea |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10086415 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Frontiers Media S.A. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-100864152023-04-12 Editorial: Inhibitors of CDK family: New perspective and rationale for drug combination in preclinical models of solid tumors Cavazzoni, Andrea Palladini, Arianna Front Oncol Oncology Frontiers Media S.A. 2023-03-28 /pmc/articles/PMC10086415/ /pubmed/37056348 http://dx.doi.org/10.3389/fonc.2023.1180650 Text en Copyright © 2023 Cavazzoni and Palladini https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| spellingShingle | Oncology Cavazzoni, Andrea Palladini, Arianna Editorial: Inhibitors of CDK family: New perspective and rationale for drug combination in preclinical models of solid tumors |
| title | Editorial: Inhibitors of CDK family: New perspective and rationale for drug combination in preclinical models of solid tumors |
| title_full | Editorial: Inhibitors of CDK family: New perspective and rationale for drug combination in preclinical models of solid tumors |
| title_fullStr | Editorial: Inhibitors of CDK family: New perspective and rationale for drug combination in preclinical models of solid tumors |
| title_full_unstemmed | Editorial: Inhibitors of CDK family: New perspective and rationale for drug combination in preclinical models of solid tumors |
| title_short | Editorial: Inhibitors of CDK family: New perspective and rationale for drug combination in preclinical models of solid tumors |
| title_sort | editorial: inhibitors of cdk family: new perspective and rationale for drug combination in preclinical models of solid tumors |
| topic | Oncology |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086415/ https://www.ncbi.nlm.nih.gov/pubmed/37056348 http://dx.doi.org/10.3389/fonc.2023.1180650 |
| work_keys_str_mv | AT cavazzoniandrea editorialinhibitorsofcdkfamilynewperspectiveandrationalefordrugcombinationinpreclinicalmodelsofsolidtumors AT palladiniarianna editorialinhibitorsofcdkfamilynewperspectiveandrationalefordrugcombinationinpreclinicalmodelsofsolidtumors |